請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39358完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃思誠(Su-Cheng Huang),林欽塘(Chin-Tarng Lin),呂勝春(Sheng-Chung Lee) | |
| dc.contributor.author | Pao-Ling Torng | en |
| dc.contributor.author | 童寶玲 | zh_TW |
| dc.date.accessioned | 2021-06-13T17:26:44Z | - |
| dc.date.available | 2006-01-01 | |
| dc.date.copyright | 2005-01-28 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-01-12 | |
| dc.identifier.citation | 第九部份：參考文獻
Al-Shahrour F D-UR, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. 2003. Afzal S, Lalani EN, Foulkes WD, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996; 74: 406-21. Afzal S, Lalani EN, Poulsom R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998; 29:155-65. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7:542-7. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression of functionally active FcRn and the differentiated budirectional transport of IgG in human placental endothelial cells. Human Immunology 2001;62:93-105. Arch RH, Gedrich RW, Thompson CB. Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun. 2000;272:936-45. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54 Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes invloved in epithelial ovarian cancer (review). In J Oncol 2000; 16:567-76. Autio-Harmainen H, Karttunen T, Hurskainen T, et al. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312-21. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000; 24:1465-79. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix maetalloproteinase 2) promoter. Mol Cell Biol 1997; 17: 6330-8. Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144:585-91. Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer 1999; 80:315-21. Brooks PC, Stromblad S, Sanders LC, et al.Localization of matrix metlloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85:683-93. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of bax and bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174-81. Cassard L, Cohen-Solal JF, Galinha A, et al. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest 2002;110:1549-57. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72. ChanJM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6. Chen Y, Du D, Wu J, et al. Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophy Res Comm 2003:311:398-404. Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-60. Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1998; 263: 6579-87. Coussens LM, Fingleton B, Matrisian LM. Matrix metallorptoeianse inhibitors and cancerL trails and tribulations. Science 2002;295:2387-92. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8. Das S, Mandal M, Chakraborti T, Mandal A, Chakraborti S. Isolation of MMP-2 from MMP-2/TIMP-2 complex: characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane.Biochim et Biophys Acta 2004:1674:158-74. Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003;20:161-9. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000;36:1258-68. Department of Health. Part 1 General Health Statistics. In Health and Vital statistics. Taiwan, ROC, 2001;pp 87. Dykxhoorn DM, Novina CD, Sharp PA. Killing the mensenger: short RNAs that silence gene expression. Nat Rev 2003;4:457-66. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phemotupe in a tumor model. PNAS 2000;97:3884-9. Finni ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In Matrix Metalloproteiases, ed. WC Parks, RP Mecham. PP. 2990356. 1998; New York: Academic. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824-54. Fossati G., Bucknall RC, Edwards SW. Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 2001;31:821-31. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-7. Goodman MT, Correa CN, Tung KH, et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer 2003; 97:2648-59. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer STatistics, CA Cancer J clin 2001; 51:15-36. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. 2002;94:1134-42. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998; 58:1707-12. Katsaros D, Yu H, Levesque MA, et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001; 37:478-85. Kolkenbrock H, Hecker-Kia A, Orgel D, Ulbrich N, Will H. Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase. Biol Chem 1997; 378:71-6. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998; 139:1338-45. Lin CT, Chan WY, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993; 68:716-27. Lin CT, Kao HJ, Lin JL, et al. Response of nasopharyngeal carcinoma cells to Epstein-Barr virus infection in vitro. Lab Invest 2000; 80:1149-60. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411:375-9. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51:5054s-9s. Lochter A, Galosy S, Muschler J, et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997; 139:1861-72. Lochter A, Sternlicht MD, Werb Z, Bissell MJ. The significance of matrix metalloproteinases during early stages of tumor progression. Ann NY Acad Sci 1998; 857:180-93. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20. Martoglio AM, Tom BD, Starkey M, et al. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med 2000; 6:750-65. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT. Circulating levels of insulin-like growth factor-II and IGF0binding protein 3 in cervical cancer. Gynecol Oncol 2003;91:486-93. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23: 40-7. McLennon SV, Martell SKY, Yue DK. Effects of mesangium glycation on matric metalloproteinase activities. Diabetes 2002;51:2612-8. Mikami Y, Hata S, Melamed J, Moriya T, Manabe T. Basement membrane material in ovarian clear cell carcinoma: correlation with growth pattern and nuclear grade. Int J Gynecol Pathol 1999;18: 52-7. Miller LD, Long PM, Wong L, et al. Optimal gene expression analysis by microarrays. Cancer Cell 2002; 2:357-61. Miyamori H, Takino T, Kobayashi Y, et al. Claudin promotes activation of pro-MMP-2 mediated by membrane-type matrix metalloprotienase. J Biol Chem 2001; 276:28204-11. Murphy G, Houbrechts A, Cockett MI, et al. The N-terminal domain of tissue inhibitor of metalloprotienases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30:8097-102. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58:50-6. Nomura, H., Fujimoto, N., Seiki, M., Mai, M., and Okada, Y. (1996). Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 69, 9-16. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60:4262-9. Ohwada M, Suzuki M, Suzuki T, et al. Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer 2001; 93: 376-80. Park EK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary eoithelial cells. Cancer Res 2001;61:7647-53. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells. Biochem Biophys Res Commun 2002;294:995-1000. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun 2002;294:988-:994. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283:139-46. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49-54. Reed JC, Bischoff JR. BIRinging chromosomes through cell division--and survivin' the experience. Cell 2000; 102:545-8. Russel, P. Surface epithelial-stromal tumors of the ovary. In: Kurman RJ. Blaustein's pathology of the female genital tract., 4th edition, p.705-782. New York: Springer-Verlag, 1994. Sakuragi N, Yamada H, Oikawa M, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 2000; 79:251-5. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120:542-7. Schimizu M, Nikaido T, Toki T, Shiozawa T, Fuji S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinoma. Cancer 1999; 85:669-77. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7:2396-404. Schwartz DR, Kardia SLR, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62:4722-9. Serov SF, SR, Sobin LH. International histologic classification of tumors, No 9, Histologic typing of ovarian tumors. (Geneva, World Health Organization). 1973. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol 1999; 11:1247-52. Shoenfeld Y. USA Patent No 5,562,902. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin. (USA). 1996. Shridhar V, Lee J, Pandita A, et al. Genetic Analysis of Early- versus Late-Stage Ovarian Tumors. Cancer Res 2001; 61:5895-904. Simpson JL, Bischoff FZ. Heritability and molecular genetic studies of endometriosis. Ann N Y Acad Sci 2002; 955:239-51. Soini Y, Hurskainen T, Hoyhtya M, et al. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994; 42:945-51. Soini Y, Paakko P, Autio-Harmainen H. Genes of laminin B1 chain, alpha 1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol 1993; 142:1622-30. Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenase-alpha- macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 1989; 264:393-401. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42 S1:S81-91. Stamenkovic I. Extracellular matrix remoodelling: the role of matrix metalloproteinase (review). J Pathol 2003; 200:448-64. Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP-2/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98:137-46. Sternlicht MD, WerbZ. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Develop Biol 2001; 17:463-516. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of ß1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 2003; 63:5850-8. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regu;ates insulin-like growth factor I receptor expression and promotes invasiveness of human cancer cells. Cancer Res 2001; 61:589-93. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161:2433-9. Wagenaar-Miller RA, Gofden L, Matrisian LM. Matrix metalloproteianses in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004;23:119-35. Wei SH, Chen CM, Stathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinoma distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246-52. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. PNAS 2001; 98:1176-81. Werness BA, Jobe JS, DiCioccio RA, Piver MS. Expression of p53 induced tumor suppressor p21waf1/cip 1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynaecol Pathol 1997; 16:149-55. Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, et al. Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999;75:91-8. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-46. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J cell Biol 2003;160:267-77. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mecnahism of B-catenon deregulation in ovarian endometrioid adenocarcinoma. Cancer Res 2001:61:8247-55. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002; 84:126-34. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2003; 19:623-9. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92:1472-89. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Comm 2003;303:1169-78. Zhou H, Kuang J, Zhong L, et al. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-93. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39358 | - |
| dc.description.abstract | 第一部份：中文摘要 | zh_TW |
| dc.description.abstract | 無 | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T17:26:44Z (GMT). No. of bitstreams: 1 ntu-94-D84421009-1.pdf: 4525458 bytes, checksum: 0d1a552e9dfd3fe2a3ac9b0e56e34355 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 一、 中文摘要…………………………………………………………………………8
二、 緒論………………………………………………………………………………9 三、 研究方法與材料…………………………………………………………………24 1. 基質消化酵素研究方法的建立……………………………………………………24 (1) 免疫組織化學染色法（Immunohistochemistry），H＆E染色 (2) 原位雜交法（In situ hybridization） (3) 酵素電泳法（Zymography） (4) 酵素活性測定（ELISA） (5) 免疫墨點吸漬法（Immunoblotting） (6) 免疫沈澱法（Immunoprecipitation） (7) 抗MMP-2之免疫墨點吸漬法（Immunoblotting of anti-MMP-2 antibody） (8) 體外侵襲力分析（In vitro invasion assay） (9) 刮劃實驗（Scratch assay） (10) 藥物實驗 (Drug Assay) 2. 卵巢上皮細胞癌株之建立及定性…………………………………………………38 (1) 癌細胞初次培養 (2) 電子顯微鏡 (3) 細胞生長速率分析 (4) 族落群形成效率（Colony forming efficiency） (5) 異體組織移植（Heterotransplantation） (6) 染色體分析 (7) 高度侵襲型細胞株之建立 3. 卵巢上皮細胞轉移基因的研究……………………………………………………41 (1) 微陣列分析（c-DNA Microarry） (2) 及時定量反轉錄聚合酶連鎖反應（QRT-PCR） (3) 基因轉殖（Transfection） (4) 核糖核酸干擾（RNAi） 4. 統計分析……………………………………………………………………………45 四、 結果……………………………………………………………………………46 1. 基質細胞之細胞外基質消化酵素與卵巢上皮細胞癌的預後有關 2. 卵巢亮細胞癌的細胞外基質消化酵素不具有活性 3. 卵巢上皮細胞癌株OVTW59的建立及定性 4. 高度侵襲型細胞之建立及定性 5. 以cDNA微陣列研究與卵巢癌轉移相關之基因 6. IGFBP-3的抑制與卵巢癌轉移有關 五、 結論……………………………………………………………………………54 六、 討論……………………………………………………………………………55 七、 展望……………………………………………………………………………69 八、 英文簡述………………………………………………………………………77 九、 參考文獻………………………………………………………………………90 十、 圖表……………………………………………………………………………99 十一、 附錄………………………………………………………………………135 | |
| dc.language.iso | zh-TW | |
| dc.title | 卵巢上皮細胞癌與侵襲相關基因之研究 | zh_TW |
| dc.title | Invasion-Related Gene Expression in Ovarian Adenocarcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 陳鈴津,許金玉,黃奇英 | |
| dc.subject.keyword | 卵巢癌, | zh_TW |
| dc.subject.keyword | ovarian carcinoma, | en |
| dc.relation.page | 136 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-01-13 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 目前未授權公開取用 | 4.42 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。